Argan Q4 Results Highlight Backlog and Cash

Argan Q4 results on March 26 showed stronger margins, a $2.9 billion backlog and a higher dividend, supporting balance sheet strength and trader interest.

March 28, 2026·2 min read
View all news articles
Centered flat-vector of a utility turbine merging into an expanding project module illustrating Argan Q4 results.

KEY TAKEAWAYS

  • Q4 revenue $262 million; gross margin 25.0% and adjusted EBITDA 21.4% of sales.
  • AGX backlog grew to $2.9 billion after $2.5 billion of new contract awards, increasing revenue visibility.
  • Cash equivalents and investments totaled $895 million with no debt and net liquidity $421 million.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Argan Q4 results on March 26, 2026, showed record quarterly profit and an expanded project backlog, leaving the company with a sizable cash position and no debt. Management raised the quarterly dividend, citing margin improvement across its businesses.

Quarter and Full-Year Results

For the quarter ended Jan. 31, 2026, Argan, Inc. (NYSE: AGX) reported revenue of $262 million, up 12.7% year over year, with a gross margin of 25.0%, a 4.5 percentage-point increase. Net income reached $49 million, or $3.47 per diluted share, while adjusted EBITDA totaled $56 million, about 21.4% of sales. Selling, general, and administrative expenses were $18 million, or 6.8% of revenue.

For fiscal 2026, the company posted revenue of $945 million, up 8.1% from the prior year. Full-year gross profit was $194 million, with a 20.5% margin, up 4.4 percentage points. Net income totaled $138 million, or $9.74 per diluted share, and EBITDA was $163 million, roughly 17.2% of revenue.

Backlog, Balance Sheet, and Dividend

Argan’s consolidated project backlog reached $2.9 billion as of Jan. 31, 2026, after adding $2.5 billion in new contract value during the fiscal year. Secondary reports indicate about 93% of the backlog relates to the utility sector. The company held $895 million in cash, cash equivalents, and investments, with net liquidity of $421 million and no debt.

The board raised the quarterly dividend to $0.50 per share, bringing total dividends for fiscal 2026 to $1.75 per share.

Operations and Management Commentary

The company announced the results in a press release, filed an 8-K, and held an investor call on March 26. Management attributed margin gains to execution in the power segment and progress on electrification projects, including the substantial completion of the Trumbull Energy Center. David Watson, president and chief executive officer, said, "Demand for our services remains exceptionally strong." The company did not provide quantitative guidance.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Nvidia Stock Falls to AI-Era Low

Nvidia Stock Falls to AI-Era Low

Nvidia stock fell to AI-era lows amid a pullback; $35.6B Q4 data-center revenue and a $1T hyperscaler backlog support traders before May 20 earnings.

Meta Entergy Louisiana Deal Promises $2B Savings

Meta Entergy Louisiana Deal Promises $2B Savings

Meta Entergy Louisiana deal funds plants and transmission for the Hyperion data center and shifts costs, reshaping investor exposure to regional utilities.

Carnival Cuts Profit Outlook as Fuel Costs Surge

Carnival Cuts Profit Outlook as Fuel Costs Surge

Carnival cuts profit outlook after rising fuel costs squeeze margins while record quarterly results and a $2.5 billion buyback complicate trader positioning.

Unity Software Q1 2026 Results Beat Guidance

Unity Software Q1 2026 Results Beat Guidance

Unity Software Q1 2026 results topped guidance as Vector drove revenue and adjusted EBITDA above outlook, sending shares higher and prompting re-rating.

AstraZeneca Tozorakimab Tops Late-Stage COPD Trials

AstraZeneca Tozorakimab Tops Late-Stage COPD Trials

AstraZeneca tozorakimab met primary endpoints in late-stage OBERON and TITANIA, spurring investor optimism ahead of full data presentation.

Novartis Acquires Excellergy for Up to $2 Billion

Novartis Acquires Excellergy for Up to $2 Billion

Novartis Acquires Excellergy, adding Exl-111 to its allergy pipeline and refocusing traders on IgE pipeline upside ahead of an expected H2 2026 close.